ENXTPA:NANOBiotechs
Nanobiotix Nanoprimer Data Add New Dimension To Cancer Platform Story
Nanobiotix reported new preclinical data on its Nanoprimer platform for lipid nanoparticle delivered recombinant DNA therapies in cancer.
The data suggest the Nanoprimer approach may help limit rapid liver clearance and related toxicity, potentially improving treatment efficacy and safety.
The results were presented at a major scientific conference, adding fresh detail to the company’s drug delivery technology story.
For investors tracking ENXTPA:NANO, the update comes with the stock...